Biological E. Limited – Unlisted Company Report

1. Company Overview

Biological E. Limited (BE) is a Hyderabad-based, privately held Indian biopharmaceutical company with a history dating back to 1953. It began as Biological Products Private Limited and became one of India’s early private-sector biological-products companies. Today, the company operates across vaccines & biologics, branded formulations, specialty generic injectables and APIs/synthetic biology.

Particular	Details
Company	Biological E. Limited
Incorporation	10 December 1953
CIN	U01120TG1953PLC001095
Status	Public, Unlisted
Registered Office	Azamabad, Hyderabad, Telangana
Paid-up Capital	~₹4.95 Cr
Authorized Capital	₹5 Cr
Managing Director	Mahima Datla
Core Sector	Pharmaceuticals / Vaccines / Biologics
Headquarters	Hyderabad, Telangana

The company is currently classified as an unlisted public company and its FY25 operating revenue was above ₹500 crore. Tofler reports FY25 total revenue of approximately ₹4,820 crore.

Official company website: Biological E. Limited

Official BE Pharmaceuticals website: BE Pharmaceuticals

2. What Does Biological E. Do?

Biological E. has built a diversified life-sciences business around four major areas:

Vaccines & Biologics

This is the company’s flagship business.

BE manufactures and supplies vaccines for infectious diseases and has developed a sizeable portfolio of WHO-prequalified products. Its portfolio includes products covering areas such as:

Pentavalent vaccines
Japanese Encephalitis
Tetanus
Diphtheria
Measles & Rubella
Typhoid
Hepatitis B
Haemophilus influenzae type B
Anti-snake venom products

The company’s pharmaceutical business states that BE currently has seven WHO-prequalified vaccines, supplies vaccines to 100+ countries, and has supplied more than 2 billion vaccine doses over the last decade.

BE Vaccines & Biologics – Global Presence

Branded Formulations

The company has an India-focused branded formulation business covering areas including:

Heparin
Enoxaparin
Noscapine-based products
Anti-infectives
Vitamins
Gastrointestinal products
Injectables
Other specialty pharmaceutical products

BE also supplies medicines to government hospitals, PSUs, the Indian Armed Forces and the domestic retail market.

Specialty Generic Injectables

BE expanded into specialty generic injectables, particularly products requiring sterile manufacturing capabilities.

Its US business operates through BE Pharmaceuticals Inc., with products supplied through hospitals, pharmacies and healthcare distributors. The company states that its US operations commenced commercially in 2019.

The portfolio includes products such as:

Enoxaparin
Daptomycin
Fosaprepitant
Glycopyrrolate
Heparin
Neostigmine
Rocuronium
Carboprost

BE Pharmaceuticals – Products

APIs & Synthetic Biology

BE is also developing API manufacturing capabilities using synthetic biology, with the stated objective of developing more cost-effective and sustainable alternatives to conventional API manufacturing processes.

3. Global Presence

Biological E. has a significant international orientation.

According to the company’s current pharmaceutical business information, its vaccines are supplied to 100+ countries, while its international operations span regulated and emerging markets.

Its international ecosystem includes operations/business presence connected with:

USA
Latin America
Asia
Africa
Europe
CIS markets

The company’s US specialty-injectables operation is based in Cary, North Carolina.

4. Financial Performance

The latest detailed FY25 figures available from Tofler show a sharp recovery in sales and operating profitability.

₹ Crore	FY21	FY22	FY23	FY24	FY25
Sales	1,274.9	2,475.8	3,659.4	2,401.1	4,670.1
Operating Profit	225.4	652.8	1,175.6	603.8	1,982.1
PAT	169.7	392.9	904.1	749.3	600.0
Net Worth	1,729.6	2,120.0	3,003.2	3,758.2	4,355.9
Borrowings	654.3	1,781.9	1,924.5	1,792.6	802.8
Debt/Equity	0.4x	0.8x	0.6x	0.5x	0.2x

FY25 sales increased approximately 94.5% YoY, while operating profit rose sharply to approximately ₹1,982 crore. PAT, however, declined to approximately ₹600 crore, partly reflecting the impact of exceptional items and the company’s financial structure.

FY25 Key Metrics

Revenue: ~₹4,670 Cr sales
Total revenue: ~₹4,820 Cr
Operating profit: ~₹1,982 Cr
PAT: ~₹600 Cr
Net worth: ~₹4,356 Cr
Borrowings: ~₹803 Cr
Operating margin: ~42.4%
Net margin: ~12.4%
ROCE: ~44.8%
Debt/Equity: ~0.2x

Important: Some databases present Biological E.’s FY25 revenue differently because of differences between revenue from operations and broader total-income presentations. For example, another financial database reports FY25 total income of ₹4,820.39 crore. Investors should therefore use the audited financial statements for valuation rather than mixing database definitions.

5. Balance Sheet

The balance sheet has improved materially from the FY23–FY24 period.

FY25:

Net worth: ~₹4,356 Cr
Borrowings: ~₹803 Cr
Assets: ~₹7,342 Cr
Debt-to-equity: ~0.2x

Compared with FY23 borrowings of roughly ₹1,925 crore, FY25 borrowings were substantially lower.

This reduction in leverage is an important financial development for an unlisted pharmaceutical company because vaccine and biologics manufacturing generally requires significant capital expenditure.

6. Competitive Strengths

1. Long operating history

Biological E. has been operating since 1953, giving it more than seven decades of experience in the life-sciences sector.

2. Vaccine manufacturing expertise

Vaccines remain the company’s strongest strategic franchise, with WHO-prequalified products and international supply relationships.

3. Large-scale manufacturing

BE has invested heavily in sterile manufacturing and vaccine infrastructure.

Its Paonta Sahib facility, acquired from Akorn India, has a large sterile injectable manufacturing setup. The acquisition was completed in 2020 for approximately US$10 million.

4. International customer base

Supplying vaccines to more than 100 countries provides geographical diversification and creates relationships with international healthcare agencies.

5. Diversification beyond vaccines

The company is expanding beyond traditional vaccines into:

Vaccines → Biologics → Specialty Injectables → APIs → Synthetic Biology

This gives BE multiple potential growth engines.

7. Corbevax – A Major Milestone

One of Biological E.’s best-known recent developments was CORBEVAX, a recombinant protein-based COVID-19 vaccine.

Biological E. partnered with Baylor College of Medicine to develop and commercialize the vaccine candidate.

The development was notable because the underlying technology was designed with affordability and accessibility for lower- and middle-income countries in mind. WIPO describes the Baylor–Biological E partnership as a case study in vaccine development and access.

Baylor College of Medicine – Biological E vaccine partnership

8. R&D Pipeline

Biological E.’s pipeline extends beyond established vaccines.

Its earlier published portfolio included development work in:

Pneumococcal conjugate vaccines
IPV
Hexavalent vaccines
HPV
RSV
Meningococcal vaccines
Typhoid conjugate vaccines
Novel biologics
Specialty injectables

The company has also stated that it intends to increase its capabilities in novel vaccines and complex pharmaceutical products.

Its specialty generic injectable R&D operation currently reports 20+ generic injectable products in development.

9. Management

Mahima Datla is the Managing Director of Biological E. Limited. Tofler lists her among the company’s key directors and reports a long tenure with the company.

The business continues to be associated with the Datla family, which has historically held significant ownership and management influence.

Historical court records document the family’s ownership and management structure, while more recent company-data sources report substantial promoter ownership. Because private-company shareholding can change through transfers and corporate actions, current investors should verify the latest MCA-filed annual return before relying on a precise promoter percentage.

10. Unlisted Share / IPO Status

Listed status

Biological E. Limited is currently unlisted.

It does not have an NSE or BSE quoted market price.

IPO

As of the latest information reviewed for this report, no confirmed IPO timetable or publicly announced DRHP-based listing schedule was identified.

Therefore, investors should not assume that an IPO is imminent simply because Biological E. is a large and well-known private pharmaceutical company.

Unlisted valuation

A reliable, current OTC market price was not identified from sufficiently authoritative public sources, so this report does not assign an indicative share price or market-cap valuation.

That is preferable to presenting an unverified dealer quote as a confirmed market value.

11. Key Growth Drivers

Vaccine demand

Global demand for affordable vaccines and immunization programs remains an important structural opportunity for manufacturers with WHO-qualified products.

International expansion

BE’s presence across 100+ countries creates room for further penetration of emerging markets.

Specialty injectables

The company’s US specialty-injectables business gives it exposure to regulated pharmaceutical markets.

Complex generics and biologics

Expansion into complex pharmaceutical products could potentially increase the company’s product mix and margins.

R&D

The company’s investments in vaccine and injectable pipelines create potential future product launches, although pipeline projects carry development and regulatory risks.

12. Key Risks

Regulatory risk

Vaccines, biologics and sterile injectables operate under stringent regulatory requirements across different countries.

Product concentration

Vaccines remain an important component of the business, making product approvals, tender cycles and public-health procurement important variables.

R&D risk

Not every vaccine or injectable in development will successfully reach commercial scale.

Unlisted-company liquidity

Because the company is privately held, investors cannot exit through a normal NSE/BSE market.

Valuation transparency

Unlike listed companies, there is no continuously observable market price, making fair-value assessment more difficult.

International regulatory risk

Expansion into the US, EU and other regulated markets exposes the company to approvals, inspections and compliance requirements.

13. UnlistedCart Takeaway

Biological E. Limited is one of India’s long-established private vaccine and biopharmaceutical companies, with a business spanning vaccines, biologics, branded formulations, specialty injectables and APIs.

The FY25 numbers show a significant rebound in sales to approximately ₹4,670 crore, operating profit of nearly ₹1,982 crore, and net worth of approximately ₹4,356 crore. At the same time, borrowings declined to around ₹803 crore, bringing debt/equity down to approximately 0.2x.

The company’s key differentiators are its long operating history, vaccine manufacturing capabilities, WHO-prequalified portfolio, international distribution network and growing specialty-injectables/R&D platform.

However, because Biological E. remains unlisted, investors should focus on the valuation at which shares are acquired, transfer/liquidity restrictions, latest audited financials and any future IPO documentation rather than relying solely on the company’s strong operating history.

Current IPO status: No confirmed IPO timetable identified in the sources reviewed.

Current unlisted price: No sufficiently reliable current OTC quote identified; therefore no price is presented.

Key Sources

Disclaimer: This report is for informational and educational purposes only and should not be treated as investment advice. Biological E. is an unlisted company, so share prices, transaction availability and liquidity can vary significantly between private transactions. Financial figures and corporate information should be independently verified from the latest audited filings and official company disclosures before making any investment decision.

For more such unlisted stocks visit UnlistedCart – Unlisted Shares